BriaCell is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care
Bria-IMT™, BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT™ is a targeted cell-based immunotherapy.
Bria-OTS™, a platform of personalized off-the-shelf cell-based immunotherapies, is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.
How Bria-IMT™ and Bria-OTS™ Destroy Cancer Cells
BriaCell’s Patented Immunotherapy
Bria-IMT™ (for MBC)
Bria-IMT™ BriaCell Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells.
Upon achieving impressive survival and clinical benefit results in a Phase 2 study, BriaCell is conducting a pivotal Phase 3 study in metastatic breast cancer, which, if successful, could lead to full approval of Bria-IMT™ in combination with an immune check point inhibitor.
Clinical data includes unprecedented activity in heavily pre-treated MBC patients who have failed antibody-drug conjugate therapy and in patients with metastases to the central nervous system.
Off-The-Shelf Personalized Immunotherapy
Bria-OTS™/Bria-OTS+™ (for MBC, prostate cancer, and other cancers)
BriaCell’s next generation personalized off-the-shelf immunotherapy, Bria-OTS™/Bria-OTS+™, awarded numerous US and international patents and supported by clinical data of its phase 3 lead program Bria-IMT™, forms the basis of BriaCell’s “OTS” strategy. BriaCell recently initiated patient enrollment in its Phase 1/2 l bucket trial in breast /prostate/lung cancer and melanoma
- Bria-IMT™ monotherapy is most effective in HLA – type matched patients
- Bria-OTS™ is engineered to express 15 unique HLA types in 4 independent cell lines
- Provides matched treatment to greater than 99% of patients
- Simple saliva test provides HLA matched personalized off the shelf Bria-OTS™ immunotherapy
- HLA matched off-the- shelf therapy is faster and less costly than other expensive and complex personalized immunotherapies
- BriaCell received a Small Business Innovation Research (SBIR) award from the National Cancer Institute
- Ongoing collaboration with the NCI
- Bria-BRES™ Phase 1/2 study open in breast cancer.
- Bucket trial with additional cancer indications planned
- Enhanced version (Bria-OTS+™) scheduled to enter the clinic 1H2025 starting with prostate cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is a clinical stage immuno-oncology company that is developing an entirely new class of targeted cellular immunotherapies to transform cancer care
- Lead drug candidate Bria-IMT™
- Pivotal Phase 3 study underway in advanced metastatic breast cancer (over 40K US deaths/year)
- Awarded Fast Track designation by FDA
- Single agent and combination check point inhibitor (+ CPI) activity
- Up to 2-fold increase in survival compared to comparable patients in the literature
- Unprecedented survival and clinical benefit even in CPI and antibody-drug conjugate (ADC) resistant patients
- Remarkable clinical efficacy data in patients with CNS metastases
- Bria-OTS™ & Bria-OTS+™: Next generation novel cell-based cancer immunotherapy platform
- Off-the-shelf and personalized
- Phase 1/2 bucket trial in breast cancer open with planned extension to prostate cancer, melanoma and lung cancer
- Next generation product candidate for prostate cancer (Bria-PROS+) scheduled to enter clinic in 1H2025
- National Cancer Institute Small Business Innovative Research (SBIR) award
- Experienced Management Team and Board of Directors; Clinical Strategy Team involved in 19 drug approvals.
What Is Immunotherapy for Cancer?
Immunotherapy is a groundbreaking approach to cancer treatment that works with the body’s natural defense system to target and destroy cancer cells. Unlike chemotherapy or radiation, which attack healthy and malignant cells, immunotherapy enhances the immune system’s ability to identify and fight tumor cells more precisely. At BriaCell, a clinical-stage immuno-oncology company, we’re at the forefront of this science and are dedicated to developing cancer immunotherapy treatments that aim to improve outcomes and quality of life for patients across multiple cancer types.
The immune system is designed to protect the body from diseases and foreign invaders. However, cancer cells can find ways to hide from this natural defense system, making them difficult to detect and eliminate. Immunotherapy works by reactivating the immune system, teaching it to recognize tumor cells as threats and respond with a targeted attack.
There are several forms of cancer immunotherapy. These include checkpoint inhibitors, which block the proteins that cancer cells use to evade detection, and cancer vaccines, which prime the immune system to identify specific tumor markers. Other methods use modified immune cells to track and destroy cancerous tissue. Each approach taps into the body’s innate power to heal and protect.
BriaCell is focused on developing innovative immunotherapy solutions tailored to specific types of cancer. Our proprietary technology aims to overcome the challenges posed by tumor evasion and resistance. By supporting the immune system in new ways, we hope to pave the way for more effective and personalized cancer treatments.
Why Immunotherapy Is the Future of Cancer Treatment
We believe immunotherapy represents the future of cancer treatment because it offers a smarter, more adaptive solution to one of medicine’s toughest challenges. As we deepen our understanding of how the immune system interacts with different types of cancer, we unlock new strategies for treatment that are less toxic and potentially more durable than conventional methods.
Traditional therapies often struggle with resistance. Tumor cells can mutate rapidly, making it difficult for static treatments to remain effective over time. Immunotherapy, by contrast, can evolve alongside the cancer. Once the immune system is trained to recognize cancer cells, it can continue to monitor and eliminate them even after initial treatment, helping to prevent recurrence.
Cancer immunotherapy holds so much promise for several reasons:
- Precision. Immunotherapy can target cancer cells while sparing healthy tissue, reducing side effects.
- Versatility. It has shown potential across multiple cancer types, including hard-to-treat cancers.
- Longevity. The immune system’s memory can provide long-term protection.
- Personalization. Treatments can be tailored to a patient’s genetic and tumor profile.
Checkpoint inhibitors have already changed the standard of care in cancers such as melanoma and non-small cell lung cancer. We expect continued progress in expanding these benefits to more patients. At BriaCell, we’re committed to advancing therapies that attack cancer and strengthen the body’s natural defenses. As research evolves, immunotherapy will likely become a central pillar of comprehensive cancer care, bringing hope to patients and families worldwide.
